| Original language | English |
|---|---|
| Pages (from-to) | 169-170 |
| Number of pages | 2 |
| Journal | British Journal of Haematology |
| Volume | 177 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1 Apr 2017 |
Keywords
- inhibitor
- T-cell acute lymphoblastic leukaemia
- TYK2
Cite this
@article{a95405531c8a4c70abff6dc26fac4d18,
title = "Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?",
keywords = "inhibitor, T-cell acute lymphoblastic leukaemia, TYK2",
author = "Curtis, {David J.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1111/bjh.14559",
language = "English",
volume = "177",
pages = "169--170",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons",
number = "2",
}
Curtis, DJ 2017, 'Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?' British Journal of Haematology, vol. 177, no. 2, pp. 169-170. https://doi.org/10.1111/bjh.14559
Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL) : what makes T-ALL TYK? / Curtis, David J.
In: British Journal of Haematology, Vol. 177, No. 2, 01.04.2017, p. 169-170.Research output: Contribution to journal › Editorial › Other › peer-review
TY - JOUR
T1 - Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL)
T2 - what makes T-ALL TYK?
AU - Curtis, David J.
PY - 2017/4/1
Y1 - 2017/4/1
KW - inhibitor
KW - T-cell acute lymphoblastic leukaemia
KW - TYK2
UR - http://www.scopus.com/inward/record.url?scp=85013480732&partnerID=8YFLogxK
U2 - 10.1111/bjh.14559
DO - 10.1111/bjh.14559
M3 - Editorial
VL - 177
SP - 169
EP - 170
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 2
ER -